Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Gastric Cancer
- Advanced Cancer
- Cervical Cancer
- Esophageal Cancer
- Hepatocellular Carcinoma
- Melanoma
- Non -Small Cell Lung Cancer
- Pancreatic Cancer
- Renal Cell Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Triple -Negative Breast Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03829501
- Collaborators
- Not Provided
- Investigators
- Study Director: Kymab Ltd Kymab Ltd
Get Well Soon